Taaleri’s continuing earnings of EUR 9.3m declined 9% y/y and were 6% below our estimate.
Redeye comments on Hexatronic’s Q1 report, showing a strong development in Data Center but with Fibe...
Redeye updates its view on NextCell following an uneventful Q2 2024/2025 report and the company’s op...
Redeye updates in EG7 ahead of Q1-results (due May 15) where we expect stable performance from EG7’s...
Redeye provides its initial take on MedCap’s Q1 2025 report, which broadly aligned with our estimate...
Redeye has updated its estimates following Heliospectra’s Q1 2025 report.
Net sales and adjusted EBITDA were below our expectations in Q1, but the company reiterated its clea...
Redeye changes its Base Case and forecasts following a mixed Q1 report from Addnode.
Minor negative revisions following Q1 report Earnings growth of ~40% in '25e Trading ~20% below sect...
Cedergrenska AB (”Cedergrenska” eller ”Koncernen”) meddelade den 28 april 2025 att Koncernen förvärv...
Hyresintäkterna steg med hela 72% till 15,6 meur och förvaltningsresultat ökade med nästan 50% till ...
NOI +75% y-o-y and -0.7% vs ABGSCe Value uplift 2.1% q-o-q, net LTV at 48.
Redeye comments on Kardium's 1-year study results for its CHS-coated Globe system.
Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system.
Redeye leaves its initial comments on Nanologica following the recent news that Flerie Invest has pa...
Fastpartners hyresintäkter och driftnetto minskade något för det första kvartalet drivet av avyttrin...
The company’s reported EBITDA was EUR 21m (Nordea est.
Redeye comments on Nitro Games' Q1 2025 report, which came in roughly in line with expectations.
Q1: -18% org. sales growth, -77% adj. EBITA growth, solid cash flow '25e-'27e adj.
Alternative MRI contrast agent for frail cancer patients Ph 3 finished and ready for FDA filing Init...
